Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2342324 | 0.84 | TAAR1 (0.46) | TAAR1OPRM1TSHRCYP2A6 | |
| Tert-Butyl Formate SCHEMBL28096453 | 0.83 | TDP1 (0.37) | TAAR1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| Ethoxycarbonyl Group SCHEMBL28096356 | 0.82 | OPRM1 (0.35) | CYP2D6OPRM1MMP2MMP9MME | |
| SCHEMBL18296314 | 0.81 | OPRM1 (0.51) | CYP2D6SLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL29119961 | 0.80 | TAAR1 (0.43) | TAAR1OPRM1TSHRCYP2A6 | |
| SCHEMBL19110540 | 0.80 | TAAR1 (0.43) | TAAR1OPRM1TSHRCYP2A6 | |
| Hydrochloric Acid SCHEMBL26117908 | 0.79 | OPRM1 (0.50) | CYP2D6SLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL19486880 | 0.79 | ESR2 (0.43) | CYP2D6SLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL655680 | 0.79 | DRD2 (0.60) | CYP2D6SLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL6925220 | 0.79 | SLC6A3 (0.39) | CYP2D6SLC6A2SLC6A4SLC6A3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| CN-118955473-A | Difunctional compounds for degrading BTK via the ubiquitin proteasome pathway | 紐力克斯治疗公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240360146-A1 | BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2024-10-31 | — | — | US | disclosed |
| CN-113412259-B | Difunctional compounds for degrading BTK via the ubiquitin proteasome pathway | 紐力克斯治疗公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240124475-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2024-04-18 | — | — | US | disclosed |
| EP-4342892-A1 | BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF | Hangzhou Healzen Therapeutics Co., Ltd. (CN) | 2024-03-27 | — | — | EP | disclosed |
| US-11914294-B2 | Positive resist composition and pattern forming process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-02-27 | — | — | US | disclosed |
| US-11866442-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| WO-2023239727-A1 | LATS INHIBITORS AND USES THEREOF | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2023-12-14 | — | — | WO | disclosed |
| EP-3077388-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | Pharmacyclics, LLC (US) | 2016-10-12 | — | — | EP | disclosed |
| CN-105960404-A | Inhibitors of bruton's tyrosine kinase | 药品循环有限责任公司 | 2016-09-21 | — | — | CN | disclosed |
| US-9382246-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382246-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382246-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2016-07-05 | — | — | US | disclosed |
| WO-2015084998-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2015-06-11 | — | — | WO | disclosed |
| US-20150158865-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2015-06-11 | — | — | US | disclosed |
| US-20150158865-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2015-06-11 | — | — | US | disclosed |
| WO-2015084998-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2015-06-11 | — | — | WO | disclosed |
| US-20150158865-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124475-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | TAAR1 4738/4885CYP2D6 3775/4885SLC6A2 4813/4885 |
| US-20240360146-A1 | BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF | BTK, ZAP70, SYK | TAAR1 4036/4885CYP2D6 2024/4885SLC6A2 3730/4885 |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, PSMB2, PSMB1 | TAAR1 4594/4885CYP2D6 2579/4885SLC6A2 4746/4885 |
| US-11866442-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | CBL, XIAP, BTK | TAAR1 4738/4885CYP2D6 3775/4885SLC6A2 4813/4885 |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, PSMB2, PSME3 | TAAR1 4332/4885CYP2D6 2938/4885SLC6A2 4792/4885 |
| US-20150158865-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | TAAR1 4262/4885CYP2D6 3109/4885SLC6A2 4615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.